Drug Prices Become Target for FDA as Chief Expands Purview
- Commissioner would prioritize additional competing generics
- Shares of generic drug makers, wholesales drop on Tuedsay.
This article is for subscribers only.
The head of the U.S. Food and Drug Administration is considering using the agency’s powers to bring more price competition to the market for generic drugs, targeting high-priced products by prioritizing the approval of additional competing treatments.
FDA Commissioner Scott Gottlieb said in an interview Monday that the agency is looking at how to push applications to the front of the line in cases where there are fewer than three competing generic manufacturers. The policy would target cases where there are few or no competing versions of drugs, which has led to high prices in some situations.